Thus, the advent of PARP inhibitors in the field of melanoma treatment has brought much excitement and potential to the field of targeted cancer therapy, particularly for patients with clinically significant genetic alterations, such as HRD and BRCA1/2 mutations. Here, BRCA1 is linked to melanoma.